10x Genomics, Inc. — Director's Dealing 2021

Nov 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-11-02

Reporting Person: Saxonov Serge (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-02	Class A Common Stock	M	5208	$5.04	Acquired	897344	Direct
2021-11-02	Class A Common Stock	M	3037	$11.48	Acquired	900381	Direct
2021-11-02	Class A Common Stock	S	3241	$160.2623	Disposed	897140	Direct
2021-11-02	Class A Common Stock	S	5946	$161.0640	Disposed	891194	Direct
2021-11-02	Class A Common Stock	S	5613	$161.9387	Disposed	885581	Direct
2021-11-02	Class A Common Stock	S	200	$163.14	Disposed	885381	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-02	Stock Option (right to buy)	$5.04	M	5208	Disposed	2028-11-02	Class A Common Stock (5208)	Direct
2021-11-02	Stock Option (right to buy)	$11.48	M	3037	Disposed	2029-05-10	Class A Common Stock (3037)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	4498	Indirect
Class A Common Stock	89960	Indirect

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $159.60 to $160.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $160.60 to $161.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $161.63 to $162.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

F6: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F7: This option, originally for 250,000 shares, of which 191,468 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F8: This option, originally for 145,786 shares, of which 94,153 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.